Siltartoxatug for tetanus protection after injury

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study enrolls about 6,000 adults with injuries requiring tetanus prophylaxis across hospitals in China. Participants choosing siltartoxatug are assigned to the treatment group, while those receiving HTIG, TAT, or F(ab')₂ form the control group. Investigators manage standard wound care and tetanus vaccination per routine practice, documenting outcomes to assess safety and effectiveness. The study is led by Zhuhai Trinomab and is conducted at The Second Affiliated Hospital Zhejiang University School of Medicine. No randomization or interventional procedures beyond routine clinical care are required.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Male or female aged ≥18 years.
* Receiving siltartoxatug for tetanus prophylaxis per its approved labeling, or receiving another passive immunizing agent (human tetanus immunoglobulin \[HTIG\], tetanus antitoxin \[TAT\], or equine F(ab')₂ fragment \[F(ab')₂\]) for tetanus prophylaxis per its labeling.
* Receiving or planned to receive standard wound management.
* Providing written informed consent by the subject or their legally authorized representative.

Exclusion Criteria:

* Life expectancy \<3 months.
* Severe cognitive impairment or other condition interfering with the assessment of tetanus development.
* Currently participating in another interventional clinical trial (observational studies are permitted).

Where it's running

• The Second Affiliated Hospital Zhejiang University School of Medicine
  Hangzhou, Zhejiang, China Recruiting

Study contacts

• Study coordinator: Xia Qu, Master
• Email: sammi.qu@trinomab.com
• Phone: +86 0756 726399

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Two-Component Diphtheria-Tetanus-Pertussis Vaccine in Adults and Adolescents

  This trial tests different doses of an absorbed acellular pertussis-containing DTP vaccine in people aged 10 and older to see how well it works and how safe it is.

  Recruiting Phase 2 Changchun BCHT Biotechnology Co. · Lishui, Zhejiang · NCT07894055

• Diphtheria, Tetanus, Pertussis, and Poliovirus Vaccine Trial in Young Children

  This is a small early-phase study testing a diphtheria, tetanus, pertussis and polio vaccine formulation in children from 2 months to 6 years to see if it is safe and can provoke an immune response.

  Recruiting Phase 1/2 Institute of Medical Biology, Chinese Academy of Medical Sciences · Chongqing, Chongqing Municipality and 2 other locations · NCT07891104

• Community spread of multiple infectious diseases in Cambodia from a One Health perspective

  This project will test how common and connected dengue, chikungunya, Zika, Japanese encephalitis, and West Nile infections are among people, animals, and the environment across Cambodia.

  Recruiting Institut Pasteur du Cambodge · Phnom Penh, Phnom Penh · NCT07358910

• Siltartoxatug injection to prevent tetanus after injury

  This registry will follow people who receive Siltartoxatug after an injury to see if it prevents tetanus and to record any side effects.

  Recruiting Zhuhai Trinomab Pharmaceutical Co., Ltd. · Shantou, Guangdong and 3 other locations · NCT07107932

• Web-based program to improve pregnant mothers' understanding of and intent to get influenza and Tdap vaccines.

  This trial will test whether a short web-based education program helps pregnant women understand and feel more likely to get influenza and Tdap vaccines.

  Recruiting at 4 sites Universiti Putra Malaysia · Bandar Baru Bangi, Selangor and 3 other locations · NCT06815250

• Tdap and RSV vaccines in pregnancy: same visit versus separate visits

  This project will see if giving the RSV and Tdap vaccines together at one prenatal visit or at separate visits is safe and protects pregnant people and their babies better.

  Recruiting at 3 sites Phase 4 Canadian Immunization Research Network · Vancouver, British Columbia and 3 other locations · NCT07097012

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.